Heal tube with controlled ventilation for the second phase Only remifentanil 1 ng mlAndersen 2010 [20]TIVA (propofol + remifentanil)Beez 2013 [21]TIVA (propofol + remifentanil)Bilotta 2014 [10]NABoetto 2015 [22]TCI-TIVA (propofol + Remifentanil)Cai 2013 [23]TCI-TIVA (propofol + Remifentanil)NKRocuronium 0.6mg kg-BISOesophageal nasopharyngeal catheter (controlled ventilation)Chacko 2013 [24]NAInitial: 50 g boluses of Relugolix biological activity fentanyl and propofol or dexmedetomidine infusion. MS-275 clinical trials Thereafter propofol (1?mg kg h-1)No medicationNK (for 1 patient propofol is described)NoNo2l min-1 oxygen via nasal cannula (spontaneous breathing)Anaesthesia Management for Awake Craniotomy15 /(Continued)Table 3. (Continued)Dosage SA(S) Anaesth. depth control Airway No LMA (controlled ventilation) MAC /AAA Management Awake phase End of surgery Use of muscle relaxants Rocuronium 0.6mg kg-StudySA(S) ManagementChaki 2014 [25]TCI-PropofolTCI: Initial 4.0g ml-1 propofol. Thereafter reduction to 1.5?.5g ml-1 NA No medication, if pain: 50 mg flurbiprofen i.v. TCI-Propofol and reinsertion of LMA Initial: Propofol 2.0?.5 mg kg-1 and remifentanil 0.025?.1 g kg-1 min-1. Thereafter: Propofol 5?0 mg kg-1 h-1 and remifentanil 0.05?.2 g kg-1 min-1. TCI: Initial: Propofol 6 g ml-1 and remifentanil 6 ng ml-1. After dural incision: reduction of propofol to 3 g ml-1 and remifentanil to 4 ng ml-1. NA Initial: dexmedetomidine 0.5?g kg-1 loading dose. Thereafter: 0.3?0.4 g kg-1 h1 dexmedetomidine supplemented with 50?100g fentanyl or 0.01?0.015g kg-1min1 remifentanil and midazolam 1-4mg Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) No medication 1. Propofol at an initial dose of 50 g kg-1 min-1 and remifentanil 0.05 g kg-1 min-1. 2. Remifentanil reduction to 0.01 g kg-1 min-1 and propofol adjusted. Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) Initial: Fentanyl 2? g kg-1 and propofol 2?.5 mg kg-1. Thereafter: additional bolus of fentanyl 1 g kg-1 (usually every 2h), and continuous propofol 50?00 g kg-1 min-1. NA No medication Remifentanil and supplementation with propofol. (Dosage NK) Propofol was resumed with 15 g kg-1 min-1 and if needed additional remifentanil 0.01 g kg-1 min-1 was applied (n = 18). No medication Remifentanil and supplementation with propofol. (Dosage NK) Reduced dosage of propofol and fentanyl As at the beginning No medication Dexmedetomidine 0.2?g kg-1min-1 and 0.005?.01g kg1 min-1remifentanil No NA No No medication (LMA removal) TCI-TIVA, propofol 6?2 g ml-1 and remifentanil 6?2 ng ml-1 No NA Reduced remifentanil 0.025?.1 g kg-1 min-1. Reduced remifentanil 0.025?.1 g kg-1 min-1 No BIS LMA (controlled ventilation)Conte 2013 [26]TIVA (propofol + remifentanil)Deras 2012 [27]TCI-TIVA (propofol + Remifentanil)LMA (controlled ventilation) for the initial asleep phase, LMA or orotracheal tube with controlled ventilation for the second phase Only clinical by Richmond agitation sedation score (RASS aim 0/-2) 3l min-1 oxygen via facemask. (spontaneous breathing)PLOS ONE | DOI:10.1371/journal.pone.0156448 May 26,NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No Nasal cannula (spontaneous breathing) NA NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing)Garavaglia 2014 [28]NAGonen 2014 [29]NAGrossman 2007 [30]NAGrossman 2013 [31]NAGupta 2007 [32]NAAnaesthesia Management for Awake Craniotomy.Heal tube with controlled ventilation for the second phase Only remifentanil 1 ng mlAndersen 2010 [20]TIVA (propofol + remifentanil)Beez 2013 [21]TIVA (propofol + remifentanil)Bilotta 2014 [10]NABoetto 2015 [22]TCI-TIVA (propofol + Remifentanil)Cai 2013 [23]TCI-TIVA (propofol + Remifentanil)NKRocuronium 0.6mg kg-BISOesophageal nasopharyngeal catheter (controlled ventilation)Chacko 2013 [24]NAInitial: 50 g boluses of fentanyl and propofol or dexmedetomidine infusion. Thereafter propofol (1?mg kg h-1)No medicationNK (for 1 patient propofol is described)NoNo2l min-1 oxygen via nasal cannula (spontaneous breathing)Anaesthesia Management for Awake Craniotomy15 /(Continued)Table 3. (Continued)Dosage SA(S) Anaesth. depth control Airway No LMA (controlled ventilation) MAC /AAA Management Awake phase End of surgery Use of muscle relaxants Rocuronium 0.6mg kg-StudySA(S) ManagementChaki 2014 [25]TCI-PropofolTCI: Initial 4.0g ml-1 propofol. Thereafter reduction to 1.5?.5g ml-1 NA No medication, if pain: 50 mg flurbiprofen i.v. TCI-Propofol and reinsertion of LMA Initial: Propofol 2.0?.5 mg kg-1 and remifentanil 0.025?.1 g kg-1 min-1. Thereafter: Propofol 5?0 mg kg-1 h-1 and remifentanil 0.05?.2 g kg-1 min-1. TCI: Initial: Propofol 6 g ml-1 and remifentanil 6 ng ml-1. After dural incision: reduction of propofol to 3 g ml-1 and remifentanil to 4 ng ml-1. NA Initial: dexmedetomidine 0.5?g kg-1 loading dose. Thereafter: 0.3?0.4 g kg-1 h1 dexmedetomidine supplemented with 50?100g fentanyl or 0.01?0.015g kg-1min1 remifentanil and midazolam 1-4mg Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) No medication 1. Propofol at an initial dose of 50 g kg-1 min-1 and remifentanil 0.05 g kg-1 min-1. 2. Remifentanil reduction to 0.01 g kg-1 min-1 and propofol adjusted. Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) Initial: Fentanyl 2? g kg-1 and propofol 2?.5 mg kg-1. Thereafter: additional bolus of fentanyl 1 g kg-1 (usually every 2h), and continuous propofol 50?00 g kg-1 min-1. NA No medication Remifentanil and supplementation with propofol. (Dosage NK) Propofol was resumed with 15 g kg-1 min-1 and if needed additional remifentanil 0.01 g kg-1 min-1 was applied (n = 18). No medication Remifentanil and supplementation with propofol. (Dosage NK) Reduced dosage of propofol and fentanyl As at the beginning No medication Dexmedetomidine 0.2?g kg-1min-1 and 0.005?.01g kg1 min-1remifentanil No NA No No medication (LMA removal) TCI-TIVA, propofol 6?2 g ml-1 and remifentanil 6?2 ng ml-1 No NA Reduced remifentanil 0.025?.1 g kg-1 min-1. Reduced remifentanil 0.025?.1 g kg-1 min-1 No BIS LMA (controlled ventilation)Conte 2013 [26]TIVA (propofol + remifentanil)Deras 2012 [27]TCI-TIVA (propofol + Remifentanil)LMA (controlled ventilation) for the initial asleep phase, LMA or orotracheal tube with controlled ventilation for the second phase Only clinical by Richmond agitation sedation score (RASS aim 0/-2) 3l min-1 oxygen via facemask. (spontaneous breathing)PLOS ONE | DOI:10.1371/journal.pone.0156448 May 26,NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No Nasal cannula (spontaneous breathing) NA NA No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing) No No 3l min-1 oxygen via nasal cannula. (spontaneous breathing)Garavaglia 2014 [28]NAGonen 2014 [29]NAGrossman 2007 [30]NAGrossman 2013 [31]NAGupta 2007 [32]NAAnaesthesia Management for Awake Craniotomy.
Related Posts
A reductively labile disulfide bonds prone to cleavage by the lysosomal cysteine proteases. We recently
A reductively labile disulfide bonds prone to cleavage by the lysosomal cysteine proteases. We recently demonstrated that nanogels with disulfide bonds within the ionic cores have been quickly degraded within the presence in the minimizing agent, which in turn accelerated the release with the incorporated drug (Kim, et al., 2010). Consequently, these final results suggest […]
Ic aspects which include extreme alcoholic beverages consumption or being overweight and metabolic syndrome. Amongst
Ic aspects which include extreme alcoholic beverages consumption or being overweight and metabolic syndrome. Amongst these suspected etiological aspects, HBV infection accounts for approximately 60 of full liver cancer scenarios in producing international locations and all-around 23 of instances in designed international locations [3]. The HBV-initiated tumorigenic course of action normally follows from or accompanies […]
Dilemma. Beitelshees et al. have recommended quite a few courses of action that
Dilemma. Beitelshees et al. have suggested a number of courses of action that physicians pursue or can pursue, one particular becoming basically to use alternatives such as prasugrel [75].TamoxifenTamoxifen, a selective jir.2014.0227 functional alleles [79]. These findings were later confirmed inside a retrospective evaluation of a considerably larger cohort of sufferers treated with adjuvant tamoxifen […]